Posters

The evaluation of a small aperture intraocular lens as a mix-and-match combination with an EDOF intraocular lens

Poster Details

First Author: C.Herbers GERMANY

Co Author(s):    I. Kaiser   J. Winters   R. Lucchesi   S. Abdassalam   M. Moftah   F. Kretz     

Abstract Details

Purpose:

Evaluation of the functional results after Mix&Match implantation of an asymmetric multifocal lens in the distant dominant eye and a small aperture IOL in the partner eye.

Setting:

Augentagesklinik Rheine, Germany.

Methods:

In 11 patients the multifocal IOL Lentis LS-313 MF20 (Oculentis, target refraction: plan) was implanted in the distant dominant eye and the small aperture IOL IC-8 (Acufocus, target refraction: -0.75 dpt) in the near dominant eye. After 3 and 6 months the visual acuity [UDVA, CDVA] was measured, the defocus curve was performed, the optical imaging quality was determined with the HD Analyzer and photopic phenomena were evaluated with the Halo & Glare Simulator. The near and intermediate range was measured with the Salzburg Reading Desk

Results:

IC-8: -Spherical equivalent of -0.48 dpt [+/- 0.36] -UCVA: 0.11 logMAR [+/-0.15], CDVA 0.07 logMAR [+/- 0.12] -Monocular defocus curve <0.2 logMAR in the range from -3.0 dpt to +1.5 dpt MF20: -Spherical equivalentE of -0.2 dpt [+/-0.33] -UCVA: 0.17 logMAR [+/-0.18], CDVA 0.09 logMAR [+/-0.17] -Monocular defocus curve < 0.67 logMAR over a range from -3.0 dpt to +1.5 dpt Mix&Match results: -UCVA is 0.08 logMAR [+/- 0.15], CDVA 0.02 logMAR [+/- 0.14] -Binocular defocus curve <0.2 over a range from -3.0 dpt to +1.50 dpt -Halo and Glare: 4 patients stated that they would not perceive any light phenomena.

Conclusions:

The Mix&Match combination of MF20 and IC-8 shows a good distance visual acuity. The defocus curve is similar in the monocular and binocular comparison. Due to the small number of patient eyes, the results should first be considered descriptively. A possible restriction of the visual field and the restricted view of the ocular fundus must be viewed critically.

Financial Disclosure:

... gains financially from competing product or procedure, ... travel has been funded, fully or partially, by a competing company, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a competing company, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... receives non-monetary benefits from a competing company, ... receives non-monetary benefits from a company producing, developing or supplying the product or procedure presented, ... receives consulting fees, retainer, or contract payments from a competing company, ... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... is employed by a competing company, ... has significant investment interest in a company producing, developing or supplying product or procedure presented